Day One Biopharmaceuticals I(DAWN)
$15.75▲6.06%
Market is closed - opens 7 PM, 19 Apr 2024
Insights
- Day One Biopharmaceuticals I is currently in a neutral trading position according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for Day One Biopharmaceuticals I stock suggests that it is range bound and no decision can be made based on this information
- Based on analysis of the Moving Averages technical indicator, Day One Biopharmaceuticals I stock is in a downtrend↘️
- Based on analysis of the Pivot Points, the current market trend for Day One Biopharmaceuticals I stock suggests that it is a good time to buy
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 50.37 | Neutral |
Stochastic | 38.61, 26.14 | Neutral |
Ultimate Oscillator | 50.32 | Neutral |
Stochastic Relative Strength Index | 31.49, 16.64 | Neutral |
Moving Average Convergence Divergence | -0.25, -0.22 | Neutral |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 14.27 | Sell |
20 | 14.92 | Sell |
50 | 15.21 | Buy |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 14.5 | Sell |
20 | 14.72 | Sell |
50 | 14.84 | Buy |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 14.37 | Buy |
20 | 14.99 | Buy |
50 | 15.23 | Neutral |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 14.29 | Sell |
20 | 14.39 | Sell |
50 | 15.07 | Sell |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 14.34 | Buy |
20 | 14.19 | Sell |
50 | 14.66 | Sell |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 15.9 |
Resistance L2 | 15.32 |
Resistance L1 | 14.96 |
Pivot Point | 14.38 |
Support L1 | 14.02 |
Support L2 | 13.44 |
Support L3 | 13.08 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.